服用达格列净的2型糖尿病合并慢性心力衰竭患者左心室舒张功能改变的观察  

Impact of Dapaglifozin on left ventricular diastolic function in type 2 diabetic patients with chronic heart failure

作　　者：吕晨燕 姜得悦 高迎 田晨光[1] LYV Chenyan;JIANG Deyue;GAO Ying(Department of Efidocrinology,The Second Affiliated Hospital,Zhengzhou University,Zhengzhou 450000,China)

机构地区：[1]郑州大学第二附属医院内分泌科,450000

出　　处：《中国糖尿病杂志》2020年第3期190-192,共3页Chinese Journal of Diabetes

基　　金：河南省科技厅科技攻关项目(182102310596).

摘　　要：目的 探讨服用达格列净对T2DM合并慢性心力衰竭(CHF)患者左心室舒张功能的影响.方法 选取2017年9月至2019年5月于我院内分泌科就诊、应用达格列净治疗、合并CHF的T2DM患者55例.收集患者基线及治疗6个月时的临床资料,比较治疗前后左心室舒张早期二尖瓣血流峰值速度(E)、二尖瓣环舒张早期运动峰值速度(e')、E/e'、左心房容积指数(LAVI)、左心室质量指数(LVMI)等变化.结果 符合入组条件并完成试验的患者共41例.达格列净治疗6个月后e'升高[(5.86 ± 1.26)vs(6.47 ± 1.45)cm/s,P<0.05],E/e'、LAVI 、LVMI 降低[(11.39 ± 2.91)vs(10.38±2.16),(30.78±4.19)vs(29.00±4.57)ml/m2,(80.39±18.89)vs(76.75±19.22)g/m2,P<0.05].结论 达格列净可改善T2DM合并CHF患者左心室舒张功能.Objective To investigate the impact of Dapagliflozin on left ventricular diastolic function in type 2 diabetes mellitus(T2DM)patients with chronic heart failure(CHF).Methods T2DM patients with CHF and treated with Dapagliflozin were enrolled in this study from the Endocrine Department of our hospital during September 2017 to May 2019.The clinical data were collected at baseline and six months after administration of Dapaglifozin.The change of velocities of early diastolic filling wave(E),Spectral pulsed-wave Doppler-derived early diastolic velocity(e’),E/e’,left atrial volume index(LAVI)and left ventricular mass index(LVMI)were measured at baseline and six months after treatment.Results A total of 41 patients fulfill the admission criteria and completed the study.Six months after treatment,e’increased[(5.86±1.26)vs(6.47±1.45)cm/s,P<0.05],E/e’,LAVI and LVMI decreased[(11.39±2.91)vs(10.38±2.16),(30.78±4.19)vs(29.00±4.57)ml/m^2,(80.39±18.89)vs(76.75±19.22)g/m^2,P<0.05].Conclusion There maybe beneficial effect of Dapagliflozin on left ventricular diastolic function parameters in T2DM patients with CHF.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 达格列净 糖尿病 2型 慢性心力衰竭 左心室舒张功能 

分 类 号：R541.6[医药卫生—心血管疾病] R587.1[医药卫生—内科学]